Descrizione

Women’s health refers to the branch of medicine that focuses on the treatment and diagnosis of diseases and conditions that affect a woman’s physical and emotional well-being. The global women’s health therapeutics market is set to increase by US$ 15.08 miliardi da 2021 A 2027, che rappresenta un tasso di crescita annuale composto (CAGR) Di 5.1% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2017-2020 e previsione a 2027 covering key market aspects like sales value for women’s health therapeutics. The global women’s health therapeutics market is segmented on the basis of disease, e regione. On the basis of disease, the global women’s health therapeutics market has been segmented into breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and polycystic ovary syndrome (PCOS). The breast cancer segment held the largest revenue share in 2020. In termini di geografia, the global women’s health therapeutics market has been segmented into Asia Pacific, Europa, Nord America, and Rest of the World (RoW).

The global women’s health therapeutics market is highly competitive. Top players covered in Global Women’s Health Therapeutics Market Study are AbbVie Inc., Amgen Inc., Asahi Kasei Corporation, AstraZeneca plc, Bayer AG, Bristol Myers Squibb (BMS), Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the women’s health therapeutics market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Disease: breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and polycystic ovary syndrome (PCOS)
Regione: Asia Pacifico, Europa, Nord America, and Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2017 A 2027

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global women’s health therapeutics market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

1. Definizione del mercato
2. Metodologia di ricerca
3. Dati di mercato e prospettive
3.1 Stime sulle dimensioni del mercato
3.2 Previsione
4. Women’s health therapeutics market by disease
4.1 Breast cancer
4.2 Postmenopausal osteoporosis
4.3 Menopause
4.4 Endometriosis
4.5 Polycystic ovary syndrome (PCOS)
5. Women’s health therapeutics market by region
5.1 Asia Pacifico
5.2 Europa
5.3 Nord America
5.4 Rest of the World (RoW)
6. Profili aziendali
6.1 AbbVie Inc.
6.2 Amgen Inc.
6.3 Asahi Kasei Corporation
6.4 AstraZeneca plc
6.5 Bayer AG
6.6 Bristol Myers Squibb (BMS)
6.7 Eisai Co., Ltd.
6.8 Eli Lilly and Company
6.9 F. Hoffmann-La Roche AG
6.10 Merck & Co., Inc.
6.11 Novartis International AG
6.12 Pfizer Inc.
6.13 Sanofi S.A.
6.14 Takeda Pharmaceutical Company Limited
7. Appendice
7.1 Informazioni su StrategyHelix
7.2 Disclaimer